Literature DB >> 26175942

AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation.

Ji-Ming Bao1, Min-Yi He2, Ya-Wei Liu3, Yong-Jie Lu4, Ying-Qia Hong5, Hai-Hua Luo6, Zhong-Lu Ren7, Shan-Chao Zhao8, Yong Jiang6.   

Abstract

Metabolomic research has revealed that metabolites play an important role in prostate cancer development and progression. Previous studies have suggested that prostate cancer cell proliferation is induced by advanced glycation end products (AGEs) exposure, but the mechanism of this induction remains unknown. This study investigated the molecular mechanisms underlying the proliferative response of prostate cancer cell to the interaction of AGEs and the receptor for advanced glycation end products (RAGE). To investigate this mechanism, we used Western blotting to evaluate the responses of the retinoblastoma (Rb), p-Rb and PI3K/Akt pathway to AGEs stimulation. We also examined the effect of knocking down Rb and blocking the PI3K/Akt pathway on AGEs induced PC-3 cell proliferation. Our results indicated that AGE-RAGE interaction enhanced Rb phosphorylation and subsequently decreased total Rb levels. Bioinformatics analysis further indicated a negative correlation between RAGE and RB1 expression in prostate cancer tissue. Furthermore, we observed that AGEs stimulation activated the PI3K/Akt signaling pathway and that blocking PI3K/Akt signaling abrogated AGEs-induced cell proliferation. We report, for the first time, that AGE-RAGE interaction enhances prostate cancer cell proliferation by phosphorylation of Rb via the PI3K/Akt signaling pathway.

Entities:  

Keywords:  AGEs; Akt; RAGE; proliferation; prostate cancer; retinoblastoma

Year:  2015        PMID: 26175942      PMCID: PMC4497440     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  49 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells.

Authors:  Chih-Hsin Tang; Yun-Ting Keng; Ju-Fang Liu
Journal:  Cancer Lett       Date:  2012-02-20       Impact factor: 8.679

3.  [Differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate].

Authors:  Bin Lu; Xian-lu Song; Li-yong Jia; Fang-li Song; Shan-chao Zhao; Yong Jiang
Journal:  Zhonghua Nan Ke Xue       Date:  2010-05

4.  History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States).

Authors:  J M Chan; D M Latini; J Cowan; J Duchane; P R Carroll
Journal:  Cancer Causes Control       Date:  2005-09       Impact factor: 2.506

5.  Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.

Authors:  J S Huang; J Y Guh; H C Chen; W C Hung; Y H Lai; L Y Chuang
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

6.  Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.

Authors:  Ning Gao; Zhuo Zhang; Bing-Hua Jiang; Xianglin Shi
Journal:  Biochem Biophys Res Commun       Date:  2003-10-31       Impact factor: 3.575

Review 7.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

8.  Conditional deletion of Rb causes early stage prostate cancer.

Authors:  Lisette A Maddison; Brent W Sutherland; Roberto J Barrios; Norman M Greenberg
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Authors:  Ankur Sharma; Clay E S Comstock; Erik S Knudsen; Khanh H Cao; Janet K Hess-Wilson; Lisa M Morey; Jason Barrera; Karen E Knudsen
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  31 in total

1.  Mechanism of 'Invigorating Qi and Promoting Blood Circulation' Drug Pair Ginseng-Danshen on Treatment of Ischemic Heart Disease Based on Network Pharmacology.

Authors:  Gao-Jie Xin; Yu-Wei Zhao; Ling-Mei Li; Fei-Fan Jia; Xiao Han; Lei Li; Hao Guo; Hong-Xu Meng; Jian-Hua Fu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2021-01-09       Impact factor: 1.978

Review 2.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

Review 3.  Hypoxia driven glycation: Mechanisms and therapeutic opportunities.

Authors:  Mohammad Imran Khan; Suvasmita Rath; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Semin Cancer Biol       Date:  2017-05-22       Impact factor: 15.707

4.  Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.

Authors:  Morgan L Zenner; Yves B Helou; Ryan J Deaton; Maria Sverdlov; Heng Wang; Andre Kajdacsy-Balla; Virgilia Macias; Cindy Voisine; Marcus Murray; Sarki A Abdulkadir; Adam B Murphy; Larisa Nonn
Journal:  Prostate       Date:  2021-12-02       Impact factor: 4.104

Review 5.  Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.

Authors:  Seigmund Wai Tsuen Lai; Edwin De Jesus Lopez Gonzalez; Tala Zoukari; Priscilla Ki; Sarah C Shuck
Journal:  Chem Res Toxicol       Date:  2022-10-05       Impact factor: 3.973

6.  PET imaging study of brown adipose tissue (BAT) activity in mice devoid of receptor for advanced glycation end products (RAGE).

Authors:  Yu-Shin Ding; Noeen Malik; Sebastian Mendoza; Daniel Tuchman; Carmen Hurtado Del Pozo; Raquel Lopez Diez; Ann-Marie Schmidt
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

7.  Silencing of advanced glycosylation and glycosylation and product-specific receptor (RAGE) inhibits the metastasis and growth of non-small cell lung cancer.

Authors:  Yan Xia Yu; Wen Chong Pan; Yu Feng Cheng
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

8.  A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer.

Authors:  Peide Huang; Fengyu Li; Zongchao Mo; Chunyu Geng; Fang Wen; Chunyan Zhang; Jia Guo; Song Wu; Lin Li; Nils Brünner; Jan Stenvang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 9.  The Role of Advanced Glycation End-Products in Cancer Disparity.

Authors:  D P Turner
Journal:  Adv Cancer Res       Date:  2016-10-12       Impact factor: 5.767

10.  SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer.

Authors:  Zhao-Ming Xiao; Dao-Jun Lv; Yu-Zhong Yu; Chong Wang; Tao Xie; Tao Wang; Xian-Lu Song; Shan-Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.